Bruno B. Bockorny, MD

Articles by Bruno B. Bockorny, MD

Dr Bockorny on the Rationale for Targeting CCR8 in Solid Tumors

May 13th 2026

Bruno B. Bockorny, MD, discusses the rationale for evaluating the anti-CCR8 antibody in a phase 1 trial in solid tumors.

Dr Bockorny on Botensilimab Plus Balstilimab in Ovarian Cancer

ByBruno B. Bockorny, MD

March 28th 2023

Bruno B. Bockorny, MD, discusses findings from a phase 1a/b trial with the combination of botensilimab and balstilimab in patients with recurrent platinum-refractory or platinum-resistant ovarian cancer.

Bruno B. Bockorny, MD

Articles by Bruno B. Bockorny, MD

Dr Bockorny on the Rationale for Targeting CCR8 in Solid Tumors

Dr Bockorny on Botensilimab Plus Balstilimab in Ovarian Cancer

Latest Updated Articles

Trending on OncLive

SERENA-6 Controversies Push the Breast Cancer Field to Consider the Future Role of ctDNA-Guided Treatment Decisions

SYNC-T SV-102 Employs Novel Mechanism to Target Immunologically ‘Cold’ Tumors in Advanced Metastatic Prostate Cancer

FDA Approval Positions Belzutifan Plus Pembrolizumab as a New Adjuvant Standard in ccRCC

FDA Approves Orca-T for Matched Donor HSCT in Hematologic Malignancies

GLP-1 Receptor Agonists, Endocrine Therapy, and Metabolic Health Comprise Holistic Breast Cancer Care